GB0424563D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0424563D0
GB0424563D0 GB0424563A GB0424563A GB0424563D0 GB 0424563 D0 GB0424563 D0 GB 0424563D0 GB 0424563 A GB0424563 A GB 0424563A GB 0424563 A GB0424563 A GB 0424563A GB 0424563 D0 GB0424563 D0 GB 0424563D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0424563A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33523293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0424563(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GB0424563A priority Critical patent/GB0424563D0/en
Publication of GB0424563D0 publication Critical patent/GB0424563D0/en
Priority to MYPI20055090A priority patent/MY148584A/en
Priority to GT200500313A priority patent/GT200500313A/es
Priority to ARP050104609A priority patent/AR054092A1/es
Priority to JP2007536128A priority patent/JP2008515954A/ja
Priority to PE2005001290A priority patent/PE20061047A1/es
Priority to RU2007120689/15A priority patent/RU2415677C2/ru
Priority to EP20100177232 priority patent/EP2286830A3/en
Priority to AU2005300692A priority patent/AU2005300692A1/en
Priority to EP05801760A priority patent/EP1812050A1/en
Priority to PCT/EP2005/011788 priority patent/WO2006048295A1/en
Priority to SG200907306-5A priority patent/SG170646A1/en
Priority to CNA2005800368845A priority patent/CN101048174A/zh
Priority to US11/718,665 priority patent/US7867499B2/en
Priority to CA002581300A priority patent/CA2581300A1/en
Priority to MX2007005430A priority patent/MX2007005430A/es
Priority to BRPI0517682-4A priority patent/BRPI0517682A/pt
Priority to NZ583688A priority patent/NZ583688A/en
Priority to KR1020077010214A priority patent/KR20070073882A/ko
Priority to TW094138839A priority patent/TWI380825B/zh
Priority to ZA200702369A priority patent/ZA200702369B/xx
Priority to IL182692A priority patent/IL182692A/en
Priority to EC2007007415A priority patent/ECSP077415A/es
Priority to TNP2007000166A priority patent/TNSN07166A1/fr
Priority to MA29899A priority patent/MA29020B1/fr
Priority to NO20072743A priority patent/NO20072743L/no
Priority to AU2010200410A priority patent/AU2010200410B2/en
Priority to US12/971,534 priority patent/US8460676B2/en
Priority to JP2011102847A priority patent/JP2011157395A/ja
Priority to US13/892,552 priority patent/US8617566B2/en
Priority to US14/085,048 priority patent/US20140079730A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0424563A 2004-11-05 2004-11-05 Organic compounds Ceased GB0424563D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GB0424563A GB0424563D0 (en) 2004-11-05 2004-11-05 Organic compounds
MYPI20055090A MY148584A (en) 2004-11-05 2005-10-28 Composition of organic compounds
GT200500313A GT200500313A (es) 2004-11-05 2005-10-28 Composicion de compuestos organicos
NZ583688A NZ583688A (en) 2004-11-05 2005-11-03 Dosage regime for the treatment of dementia using a VLP and amyloid-beta-1-42 peptide
CNA2005800368845A CN101048174A (zh) 2004-11-05 2005-11-03 包含VLP和淀粉样肽β的组合物
US11/718,665 US7867499B2 (en) 2004-11-05 2005-11-03 Methods of treating dementia by administering virus-like particles coupled to Aβ
KR1020077010214A KR20070073882A (ko) 2004-11-05 2005-11-03 Ｖｌｐ 및 아밀로이드-베타 펩티드를 포함하는 조성물
PE2005001290A PE20061047A1 (es) 2004-11-05 2005-11-03 COMPOSICION FARMACEUTICA QUE COMPRENDE UN PEPTIDO ß-AMILOIDE
RU2007120689/15A RU2415677C2 (ru) 2004-11-05 2005-11-03 Композиция, содержащая вирусоподобную частицу (впч) и пептид амилоид-бета
EP20100177232 EP2286830A3 (en) 2004-11-05 2005-11-03 Composition comprising vlp and amyloid-beta peptide
AU2005300692A AU2005300692A1 (en) 2004-11-05 2005-11-03 Composition comprising VLP and amyloid-beta peptide
EP05801760A EP1812050A1 (en) 2004-11-05 2005-11-03 Composition comprising vlp and amyloid-beta peptide
PCT/EP2005/011788 WO2006048295A1 (en) 2004-11-05 2005-11-03 Composition compri sing vlp and amyloid - beta peptide
SG200907306-5A SG170646A1 (en) 2004-11-05 2005-11-03 Composition comprising vlp and amyloid-beta peptide
JP2007536128A JP2008515954A (ja) 2004-11-05 2005-11-03 ＶＬＰおよびアミロイドβペプチドを含む組成物
ARP050104609A AR054092A1 (es) 2004-11-05 2005-11-03 Composicion de compuestos organicos
CA002581300A CA2581300A1 (en) 2004-11-05 2005-11-03 Composition comprising vlp and amyloid-beta peptide
MX2007005430A MX2007005430A (es) 2004-11-05 2005-11-03 Composicion que comprende particula tipo virus (vlp) y peptido amiloide-beta.
BRPI0517682-4A BRPI0517682A (pt) 2004-11-05 2005-11-03 composição contendo vlp e peptìdeo amilóide-beta
TW094138839A TWI380825B (zh) 2004-11-05 2005-11-04 由病毒樣粒子(VLP)及Aβ-1-42肽之一片段組成之構築體、包含其之組合及商業包裝及其用途
ZA200702369A ZA200702369B (en) 2004-11-05 2007-03-22 Compositions comprising VLP and amyloid-beta peptide
IL182692A IL182692A (en) 2004-11-05 2007-04-19 Use of vlp and amyloid-beta peptide for the manufacture of pharmaceutical compositions for the treatment of dementia
EC2007007415A ECSP077415A (es) 2004-11-05 2007-04-24 Composición que comprende partícula tipo virus (vlp) y péptido amiloide-beta
TNP2007000166A TNSN07166A1 (en) 2004-11-05 2007-05-04 Composition comprising vlp and amyloid-beta peptide
MA29899A MA29020B1 (fr) 2004-11-05 2007-05-14 Composition contenant une vlp et un peptide amyloide beta
NO20072743A NO20072743L (no) 2004-11-05 2007-05-30 Sammensetning omfattende VLP og amyloid-betapeptid
AU2010200410A AU2010200410B2 (en) 2004-11-05 2010-02-04 Composition comprising VLP and amyloid-beta peptide
US12/971,534 US8460676B2 (en) 2004-11-05 2010-12-17 Composition comprising VLP and amyloid beta peptide
JP2011102847A JP2011157395A (ja) 2004-11-05 2011-05-02 ＶＬＰおよびアミロイドβペプチドを含む組成物
US13/892,552 US8617566B2 (en) 2004-11-05 2013-05-13 Composition comprising VLP and amyloid beta peptide
US14/085,048 US20140079730A1 (en) 2004-11-05 2013-11-20 Composition comprising vlp and amyloid beta peptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0424563A GB0424563D0 (en) 2004-11-05 2004-11-05 Organic compounds

Publications (1)

Publication Number Publication Date
GB0424563D0 true GB0424563D0 (en) 2004-12-08

Family

ID=33523293

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0424563A Ceased GB0424563D0 (en) 2004-11-05 2004-11-05 Organic compounds

Country Status (25)

Country Link
US (4) US7867499B2 (https=)
EP (2) EP2286830A3 (https=)
JP (2) JP2008515954A (https=)
KR (1) KR20070073882A (https=)
CN (1) CN101048174A (https=)
AR (1) AR054092A1 (https=)
AU (2) AU2005300692A1 (https=)
BR (1) BRPI0517682A (https=)
CA (1) CA2581300A1 (https=)
EC (1) ECSP077415A (https=)
GB (1) GB0424563D0 (https=)
GT (1) GT200500313A (https=)
IL (1) IL182692A (https=)
MA (1) MA29020B1 (https=)
MX (1) MX2007005430A (https=)
MY (1) MY148584A (https=)
NO (1) NO20072743L (https=)
NZ (1) NZ583688A (https=)
PE (1) PE20061047A1 (https=)
RU (1) RU2415677C2 (https=)
SG (1) SG170646A1 (https=)
TN (1) TNSN07166A1 (https=)
TW (1) TWI380825B (https=)
WO (1) WO2006048295A1 (https=)
ZA (1) ZA200702369B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
BR112012024708A2 (pt) * 2010-03-29 2016-06-07 Novartis Ag composição de compostos orgânicos
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0038154B1 (en) 1980-04-15 1983-09-21 Beecham Group Plc Allergens modified with polysarcosines
US5204096A (en) 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01501064A (ja) 1986-09-22 1989-04-13 エモリ　ユニバーシティ ワクチンとその製法
US5143726A (en) 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
GB8903313D0 (en) 1989-02-14 1989-04-05 Wellcome Found Conjugates
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5142726A (en) * 1991-04-03 1992-09-01 Mann Robert F Adjustable bristle length toothbrush
GB9114003D0 (en) 1991-06-28 1991-08-14 Mastico Robert A Chimaeric protein
ZA934199B (en) 1992-06-18 1994-01-10 Akzo Nv Carrier system against gnrh
US6004763A (en) 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
EP0678034B1 (en) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Inducing cytotoxic t lymphocyte responses
US6180771B1 (en) 1993-12-08 2001-01-30 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p III, and uses therefor
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
JPH09202735A (ja) 1996-01-25 1997-08-05 Nof Corp リポソーム型アレルギー治療薬
US5786161A (en) 1996-06-06 1998-07-28 Miltenyi Biotec. Gmbh Isolation and characterization of allergen-binding cells for diagnosis of hypersensitivity
SE9604815D0 (sv) 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A metod of diagnosis
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP2006303A1 (en) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US6054312A (en) 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1033998B1 (en) 1997-12-03 2005-10-19 Neuralab, Ltd. Suppressing beta-amyloid-related changes in alzheimer's disease
WO1999040934A1 (en) 1998-02-12 1999-08-19 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US5990085A (en) 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
US6380364B1 (en) 1998-11-23 2002-04-30 Loyola University Of Chicago Chimeric biotin-binding papillomavirus protein
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
EA004497B1 (ru) 1998-12-04 2004-04-29 Байоджен, Инк. Коровые антигенные частицы hbv с множественными иммуногенными компонентами, связанными посредством пептидных лигандов
CN1520423A (zh) 1999-02-25 2004-08-11 ʷ��˿�������ȳ�ķ���޹�˾ 来源于IgE的Cε3或Cε4区的抗原决定基或拟表位,其拮抗物,及其治疗用途
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
WO2001053457A2 (en) 2000-01-21 2001-07-26 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
ES2248283T3 (es) 2000-02-21 2006-03-16 Pharmexa A/S Nuevo procedimiento para reducir los niveles de amiloide.
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US8519005B2 (en) * 2000-07-27 2013-08-27 Thomas N. Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US20030219459A1 (en) 2002-01-18 2003-11-27 Cytos Biotechnology Ag Prion protein carrier-conjugates
EP2351770A1 (en) 2002-07-17 2011-08-03 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
MXPA04011247A (es) 2002-07-19 2005-02-17 Cytos Biotechnology Ag Conjugados portadores de grelina.
SI1524994T1 (sl) * 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
WO2004016262A1 (ja) 2002-08-12 2004-02-26 Kyowa Hakko Kogyo Co., Ltd. アミノ酸含有チュアブル錠
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
JP2011157395A (ja) 2011-08-18
US20090060899A1 (en) 2009-03-05
ECSP077415A (es) 2007-05-30
AU2010200410B2 (en) 2011-10-13
EP2286830A3 (en) 2011-03-30
TW200621288A (en) 2006-07-01
US20130252889A1 (en) 2013-09-26
IL182692A0 (en) 2007-09-20
TNSN07166A1 (en) 2008-11-21
US8460676B2 (en) 2013-06-11
US7867499B2 (en) 2011-01-11
KR20070073882A (ko) 2007-07-10
RU2007120689A (ru) 2008-12-20
BRPI0517682A (pt) 2008-10-14
CN101048174A (zh) 2007-10-03
RU2415677C2 (ru) 2011-04-10
JP2008515954A (ja) 2008-05-15
CA2581300A1 (en) 2006-05-11
US20110086036A1 (en) 2011-04-14
GT200500313A (es) 2006-12-18
AR054092A1 (es) 2007-06-06
AU2010200410A1 (en) 2010-02-25
US20140079730A1 (en) 2014-03-20
NO20072743L (no) 2007-05-30
AU2005300692A1 (en) 2006-05-11
MA29020B1 (fr) 2007-11-01
NZ583688A (en) 2011-10-28
EP1812050A1 (en) 2007-08-01
PE20061047A1 (es) 2006-11-07
IL182692A (en) 2010-12-30
MY148584A (en) 2013-04-30
MX2007005430A (es) 2007-05-18
WO2006048295A1 (en) 2006-05-11
SG170646A1 (en) 2011-05-30
ZA200702369B (en) 2008-09-25
US8617566B2 (en) 2013-12-31
EP2286830A2 (en) 2011-02-23
TWI380825B (zh) 2013-01-01

Similar Documents

Publication Publication Date Title
GB0410712D0 (en) Organic compounds
GB0409921D0 (en) Organic compounds
GB0407723D0 (en) Organic compounds
GB0405289D0 (en) Organic compounds
GB0404434D0 (en) Organic compounds
GB0401334D0 (en) Organic compounds
GB0402797D0 (en) Organic compounds
GB0408078D0 (en) Organic compounds
GB0412768D0 (en) Organic compounds
GB0400781D0 (en) Organic compounds
GB0403254D0 (en) Organic compounds
GB0406515D0 (en) Organic compounds
GB0424563D0 (en) Organic compounds
GB0409236D0 (en) Organic compounds
GB0405723D0 (en) Organic compounds
GB0406240D0 (en) Organic compounds
GB0407607D0 (en) Organic compounds
GB0407468D0 (en) Organic compounds
GB0405034D0 (en) Organic compounds
GB0405898D0 (en) Organic compounds
GB0406379D0 (en) Organic compounds
GB0409602D0 (en) Organic compounds
GB0408066D0 (en) Organic compounds
GB0408060D0 (en) Organic compounds
GB0410264D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)